Company Profile

Kadmon Holdings, Inc. is a biopharmaceutical company, which is engaged in discovering, developing, and delivering therapies for unmet medical needs. The Company's clinical pipeline includes treatments for immune and fibrotic diseases as well as immuno-oncology therapies. It is developing oral small molecule inhibitors of Rho-associated coiled-coil kinase (ROCK) to treat immune and fibrotic diseases. Its advanced product candidate, Belumosudil (KD025) is an orally administered, selective small molecule inhibitor of Rho-associated coiled-coil kinase 2 (ROCK2). The Company has a biologics research platform focused on the development of immuno-oncology therapeutics, specifically, IL-15-containing fusion proteins for the treatment of cancer. Its advanced candidate from the biologics platform, KD033, is an anti-PD-L1/IL-15 fusion protein designed to stimulate an immune response directed to the tumor microenvironment. IL-15 is a cytokine that expands key tumor-fighting immune cell types.

Employees

127

Sector

Pharmaceuticals

More about the company

21/12/21	Sanofi in $1 bln deal to buy U.S.-based Amunix Pharma	RE
01/12/21	Sanofi to buy Origimm Biotechnology for acne vaccine candidate	RE
10/11/21	Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P Global BMI Index	CI
10/11/21	Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P TMI Index	CI
10/11/21	Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from S&P Biotechnology Select Industry Index	CI
09/11/21	Sanofi Closes on Kadmon Acquisition	MT
09/11/21	Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from NASDAQ Composite Index	CI
08/11/21	Sanofi completed the acquisition of Kadmon Holdings, Inc..	CI
08/11/21	Kadmon Holdings, Inc.(NasdaqGS:KDMN) dropped from NASDAQ Biotechnology Index	CI
04/11/21	Kadmon Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	CI
04/11/21	Earnings Flash (KDMN) KADMON HOLDINGS Reports Q3 Revenue $14.7M	MT
21/10/21	Kadmon : Health Care Stocks Edging Higher At Close	MT
21/10/21	Kadmon : Announces Expiration of HSR Waiting Period in Sanofi Deal	MT

14/09/21	Kadmon : Mizuho Securities Downgrades Kadmon Holdings to Neutral from Buy, Adjusts Price Target to $9.50 from $13	MT
10/09/21	Kadmon : UBS Downgrades Kadmon Holdings to Neutral From Buy, Adjusts PT to $9.50 From $9	MT
09/09/21	Kadmon : Oppenheimer Suspends Rating for Kadmon Holdings Following Sanofi Merger	MT
09/09/21	Kadmon : Jefferies Downgrades Kadmon Holdings to Hold from Buy, Adjusts Price Target to $9.50 from $10	MT
19/07/21	Kadmon : Oppenheimer Adjusts Kadmon Holdings PT to $9 From $8, Maintains Outperform Rating	MT

09/11/21	Sanofi completes acquisition of Kadmon - Form 8-K	PU
09/11/21	KADMON HOLDINGS, INC. : Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control or Registrant, Change in Directors or Principal Officers, Amendme (form 8-K)	AQ
05/11/21	KADMON HOLDINGS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K)	AQ
04/11/21	Kadmon Provides Business Update and Reports Third Quarter 2021 Financial Results	PU
04/11/21	KADMON HOLDINGS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	AQ

04/02/22	Sanofi wächst weiter - Neurodermitis-Mittel bringt Schwung
07/01/22	Sanofi : renforce dans l'Intelligence Artificielle appliquée à l'oncologie et l'immunologie
21/12/21	Weiterer Milliardendeal: Sanofi will US-Krebsspezialisten Amunix übernehmen
21/12/21	Sanofi : La valeur du jour à Paris Sanofi signe une nouvelle acquisition
21/12/21	Sanofi übernimmt US-Krebsspezialisten für gut eine Milliarde Dollar

Manager	Title	Age	Since
Gustavo J. Pesquin CEO	Chief Executive Officer	56	08/11/2021
Steven Meehan DFI	Director of Finance/CFO	62	07/02/2019
John Ryan CTO	Chief Tech/Sci/R&D Officer	82	31/12/2010

Kadmon Holdings, Inc. Share Price

Stocks

KDMN

US48283N1063

Pharmaceuticals

Latest news: Kadmon Holdings, Inc.

Analysts' recommendations: Kadmon Holdings, Inc.

Press Releases: Kadmon Holdings, Inc.

News in other languages: Kadmon Holdings, Inc.

Quotes and Performance

Managers and Directors: Kadmon Holdings, Inc.

Latest insider transactions

Biopharmaceuticals

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/11/21	Arthur Kirsch	Issuer sale	Director	376,112	0.2134%
09/11/21	David Cohen	Issuer sale	Director	346,944	0.1969%
09/11/21	Steven Meehan	Issuer sale	Chief Financial Officer	1,994,909	1.1319%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
KADMON HOLDINGS, INC.	+0.21%	+0.42%	-	-	1.7B
ELI LILLY AND COMPANY	-2.54%	+1.31%	+54.27%	+114.96%	1,135B
JOHNSON & JOHNSON	-1.42%	+3.23%	+38.56%	+74.44%	635B
ABBVIE INC.	+0.16%	+0.08%	+25.29%	+95.23%	505B
ROCHE HOLDING AG	-0.31%	+3.09%	+44.14%	+64.80%	378B
MERCK & CO., INC.	-1.34%	-0.47%	+66.04%	+41.00%	358B
NOVARTIS AG	-0.68%	+2.65%	+22.98%	+50.39%	295B
ASTRAZENECA PLC	-1.20%	+3.04%	+2.33%	+22.86%	266B
AMGEN INC.	-1.79%	+1.57%	+50.56%	+59.08%	237B
GILEAD SCIENCES, INC.	-0.73%	-0.10%	+29.02%	+99.67%	193B
Average	-0.96%	+2.17%	+37.02%	+69.16%	444.85B
Weighted average by Cap.	-1.35%	+2.66%	+41.02%	+79.75%